The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized…
By P. Reilly, T. Lehr, S. Haertter, S. Connolly, S. Yusuf, J. Eikelboom, M. Ezekowitz, G. Nehmiz, Susan Wang, L. Wallentin. Journal of the American College of Cardiology, 2014
863 citations recorded by the source corpus.
Subfields: Cardiology and Cardiovascular Medicine, Internal Medicine
View Paper: https://www.semanticscholar.org/paper/00f98140e81ed2bb1847352056f1c62a19c29a46
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Cardiology and Cardiovascular Medicine
Citations in the corpus
- The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. (2018, background): “warfarin was observed(28); however, this was in an unselected AF population and not in selected high-risk patients in whom plasma levels may be increased and the benefit of a reduction in major bleeding may be lost.(152,155) For edoxaban 30/ 15 mg OD a 41% higher ischaemic stroke risk compared with ”